Anti-TNF antibodies were the best selling class of biologics in 2008 with total sales of US$ 16.4 bln. The most successful biologic brand in 2008 was the anti-TNF fusion protein Enbrel (etanercept) with sales of US$ 6.4 bln; the biologic with the strongest growth in 2008 was the anti-TNF antibody adalimumab from Abbott (+ US$ 1.5 bln / + 48 % vs 2007). Erythropoietins fell down to position 4 with 2008 sales of US$ 10 bln, superseded by the class of anti-cancer antibodies (US$ 15.6 bln) and insulin products (US$ 10.9 bln) due to the continuing success of insulin analogs. The 13 major classes of biologics together posted 2008 sales of US$ 80.6 bln of which 43.4 % originated from antibody sales. The second cluster of successful classes of biologics consisted of interferon beta (US$ 5.4 bln), G-CSF (US$ 5.2 bln) and recombinant coagulation factors (US$ 4.9 bln). 2008 sales of enzyme replacement therapies recorded a strong growth from US$ 2.3 bln in 2007 to US$ 2.8 bln in 2008. These results and more were found in an elaboration prepared by La Merie Business Intelligence and published in a complimentary report on March 9, 2009. The document entitled “TOP 20 Biologics 2008” can be acquired as a free download at La Merie’s News Center and Online Store PipelineReview.com

The “TOP 20 Biologics 2008” report presents in tabular format 2008 sales figures of the TOP 20 selling single biologic products, of the 13 top-selling classes of recombinant biologicals, i.e. proteins and antibodies (excluding vaccines and peptides), and in detail the sales figures of the individual products of the 13 top selling classes of biologics plus selected other antibodies and proteins and successful peptide drugs. In addition, information is provided on brand and generic names, target, class of compound, originator and licensee companies, product category and major indications. All information is fully referenced by a hyperlink leading to the original source of information.

Download FREE Report
 

---